Loading data for CAPR — first visit, this takes a few seconds.

알림

Capricor Therapeutics Inc... (CAPR)

NasdaqGS: CAPR · 실시간 가격 · USD

9.36

+1.07 (12.91%)

종가 기준: Aug 26, 2026, 3:59 PM

9.41

+0.53%

애프터마켓: 7:59 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

12.91% (1D)

매수호가	8.25
시가총액	544.18M
매출 (ttm)	n/a
순이익 (ttm)	-129.42M
	0.53
	-2.76
	n/a
	-5.9
P/B (ttm)	2.21
P/S (ttm)	n/a
실적 발표일	Nov 10, 2026

매도호가	10.44
거래량	11,895,563
평균 거래량 (20일)	5,466,185
시가	8.22
전일 종가	8.29
일중 범위	8.05 - 9.88
52주 범위	2.96 - 40.37
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

CAPR 소개

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome prot...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 13, 2007

직원 수 231

상장 거래소 NasdaqGS

티커 CAPR

웹사이트 https://www.capricor.com

전체 기업 정보

재무 실적

2025년 Capricor Therapeutics의 매출은 0로, 전년 22.27M 대비 -100% 감소했습니다. 순이익은 -105.04M로, 159.58% 증가했습니다.

재무제표

어닝 서프라이즈

Capricor Therapeutics가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -0.7 예상치 하회 -0.12, 및 -32.08% 전년 대비 감소.

다음 실적 발표

Capricor Therapeutics Inc.의 실적 발표 예정일은 Nov 10, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2일 전 · Stocktwits

CAPR Stock Climbs On FDA’s Three-Month Deramiocel Extension — HC Wainwright Sticks To Neutral, Flags High Rejection Risk

Capricor said on Monday that the FDA pushed back the deadline to decide on the company’s deramiocel application from August 22 to November 22.

2일 전 · MT Newswires

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks decreased late Monday afternoon, with the NYSE Healthcare Index and the State Stre

2일 전 · MT Newswires

Sector Update: Healthcare Stocks Decline in Afternoon Trading

Healthcare stocks were decreasing Monday afternoon, with the NYSE Healthcare Index and the State Str

2일 전 · Stocktwits

Why Is CAPR Stock Rising Today?

The U.S. Food and Drug Administration extended its review of the biotech firm’s experimental Duchenne muscular dystrophy treatment, Deramiocel, by three months.

2일 전 · InvestorsHub

Capricor Therapeutics Deramiocel PDUFA Date Extended to November as FDA Reviews BLA Amendment

Capricor Therapeutics (NASDAQ:CAPR) faces a three-month extension to the FDA review timeline for Deramiocel after the agency moved the PDUFA target action date for the Duchenne muscular dystrophy cell...

2 페이지 중 1

Capricor Therapeutics Inc... (CAPR)